FormDSignal
45

Tempest Therapeutics closes $7.5M raise in Brisbane biotech

Company raise · Closed · BRISBANE, CA · Form D filed 2026-10-14

Tempest Therapeutics, a Delaware corporation in biotechnology, closed a $7.5M offering under Regulation D exemption 6(b) on September 15, 2026. The company engaged H.C. Wainwright & Co., LLC as placement agent and has raised from one investor so far.

Placement agent engagedother

Why now — by persona

  • Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
  • Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock

People on the filing

Matthew AngelPresident and Chief Executive Officer
Constance AmesChief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary
John David YeeDirector
William Drake RicheyDirector
Nancy Freda-SmithDirector
John Wilbert FrederickDirector

Signed by Matthew Angel, President and Chief Executive Officer.

Placement agents / sales compensation: H.C. Wainwright & Co., LLC

Filing contact

The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.

Other filings by this issuer